Efficacy of intermediate-dose oral erythromycin on very low birth weight infants with feeding intolerance.

doi:10.1016/j.pedneo.2011.11.007

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/10876

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/10876

Title:	Efficacy of intermediate-dose oral erythromycin on very low birth weight infants with feeding intolerance.
Authors:	Ng, YY Su, PH Chen, JY Quek, YW Hu, JM Lee, IC Lee, HS Chang, HP
Contributors:	中山醫學大學
Date:	2012
Issue Date:	2015-05-25T09:42:35Z (UTC)
ISSN:	1875-9572
Abstract:	Abstract BACKGROUND: Erythromycin is generally used as a prokinetic agent for the treatment of feeding intolerance in preterm infants; however, results from previous studies significantly vary due to different medication dosages, routes of administration, and therapy durations. The effectiveness and safety of intermediate-dose oral erythromycin in very low birth weight (VLBW) infants with feeding intolerance was examined in this study. METHODS: Between November 2007 and August 2009, 45 VLBW infants with feeding intolerance, who were all at least 14 days old, were randomly allocated to a treatment group and administered 5mg/kg oral erythromycin every 6hours for 14 days (n=19). Another set of randomly selected infants was allocated to the control group, which was not administered erythromycin (n=26). RESULTS: The number of days required to achieve full enteral feeding (36.5±7.4 vs. 54.7±23.3 days, respectively; p=0.01), the duration of parenteral nutrition (p<0.05), and the time required to achieve a body weight ≥2500g (p<0.05) were significantly shorter in the erythromycin group compared with the control group. The incidence of parenteral nutrition-associated cholestasis (PNAC) and necrotizing enterocolitis (NEC) ≥ stage II after 14 days of treatment were significantly lower (p<0.05) in the erythromycin group. No significant differences were observed in terms of the incidences of sepsis, bronchopulmonary dysplasia, or retinopathy of prematurity. No adverse effects were associated with erythromycin treatment. CONCLUSIONS: Intermediate-dose oral erythromycin is effective and safe for the treatment of feeding intolerance in VLBW infants. The incidences of PNAC and ≥ stage II NEC were significant lower in the erythromycin group. Copyright © 2012. Published by Elsevier B.V. Comment in Erythromycin for the treatment of feeding intolerance in preterm infants. [Pediatr Neonatol. 2012]
URI:	https://ir.csmu.edu.tw:8080/ir/handle/310902500/10876 http://dx.doi.org/10.1016/j.pedneo.2011.11.007
Relation:	Pediatr Neonatol. 2012 Feb;53(1):34-40.
Appears in Collections:	[醫學系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html	期刊論文	0Kb	HTML	299	View/Open

View Licence

Loading...